Ovarian cancer is the leading cause of gynecological cancer-related death. Drug resistance
is the bottleneck in ovarian cancer treatment. The increasing use of novel drugs in clinical …

R-2-hydroxyglutarate (R-2HG), produced at high levels by mutant isocitrate dehydrogenase
1/2 (IDH1/2) enzymes, was reported as an oncometabolite. We show here that R-2HG also …

N 6 -Methyladenosine (m 6 A) is the most abundant RNA modification in mammal mRNAs
and increasing evidence suggests the key roles of m 6 A in human tumorigenesis. However, …

METTL3 encodes the predominant catalytic enzyme to promote m 6 A methylation in nucleus.
Recently, accumulating evidence has shown the expression of METTL3 in cytoplasm, but …

In this contribution, recent advances in new classes of efficient metal-TADF complexes,
especially those of Au(I), Au(III), and W(VI), and their application in OLEDs are reviewed. The …

Background Since FTO was recognized as the first m 6 A demethylase, the understanding
of its biological function has been widely expanded. However, the role of FTO in cervical …

Background The Lymphadenectomy in Ovarian Neoplasms (LION) study revealed that
systemic lymphadenectomy did not bring survival benefit for advanced ovarian cancer patients …

Importance The efficacy of niraparib maintenance therapy with an individualized starting dose
(ISD) warrants further investigation in a broad population with newly diagnosed advanced …

Cervical cancer (CC) that is caused by high-risk human papillomavirus (HPV) remains a
significant public health problem worldwide. HPV integration sites can be silent or actively …

Strand-selection is the final step of microRNA biogenesis in which functional mature miRNAs
are generated from one or both arms of precursor. The preference of strand-selection is …